Actively Recruiting

Phase Not Applicable
Age: 55Years +
All Genders
NCT04796545

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

Led by VisionCare, Inc. · Updated on 2026-02-10

76

Participants Needed

13

Research Sites

324 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD). Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.

CONDITIONS

Official Title

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

Who Can Participate

Age: 55Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be 55 years of age or older.
  • Have retinal findings of geographic atrophy or disciform scar with foveal involvement.
  • Have evidence of cataract.
  • Have best-corrected distance visual acuity no better than 20/80 and no worse than 20/800 in both eyes.
  • Have adequate peripheral vision in the eye not scheduled for surgery.
  • Achieve at least a five-letter improvement on the ETDRS chart in the eye scheduled for surgery using a 2.8X external telescope simulator.
  • Have an anterior chamber depth of at least 2.5 mm in the eye scheduled for surgery.
  • Be willing to participate in post-operative training for the implant.
  • Review and sign informed consent.
  • Have adequate understanding of the local language and willingness to comply with study requirements.
Not Eligible

You will not qualify if you...

  • Evidence of active choroidal neovascularization or treatment for it within the past six months.
  • Any eye disease that compromises peripheral vision in the fellow eye.
  • History of steroid-responsive intraocular pressure rise, uncontrolled glaucoma, or preoperative intraocular pressure over 22 mm Hg.
  • Corneal guttata.
  • Known sensitivity to post-operative medications.
  • Significant communication impairment or severe neurological disorders.
  • Previous intraocular or corneal surgery in the operative eye.
  • Eye condition causing a tendency to rub the eye.
  • Ophthalmic surgery within 30 days before implant surgery.
  • Operative eye with myopia greater than 6.0 D, hyperopia greater than 4.0 D, axial length less than 21 mm, endothelial cell density less than 1600 cells/mm², or narrow angle less than Schaffer grade 2.
  • Inflammatory ocular disease.
  • Corneal stromal or endothelial dystrophies.
  • Zonular weakness or lens instability.
  • Diabetic retinopathy.
  • Untreated retinal tears.
  • Retinal vascular disease.
  • Optic nerve disease.
  • History of retinal detachment.
  • Retinitis pigmentosa.
  • Intraocular tumor.
  • Participation in other investigational studies within 30 days or planned during this study.
  • Employment or relative employment with the CRO, Sponsor, or Sponsor representative.
  • Any condition that may pose significant risk, confound results, or interfere with participation as judged by the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

UZ Brussel

Brussels, Belgium

Actively Recruiting

2

Centre d'Ophtalmologie Paradis-Monticelli

Marseille, France

Actively Recruiting

3

Hélios Ophtalmologie, Saint-Jean-de-Luz

Saint-Jean-de-Luz, France

Actively Recruiting

4

CHRU de Strasbourg

Strasbourg, France

Actively Recruiting

5

Augenklinik Städtisches Klinikum Karlsruhe

Karlsruhe, Germany

Terminated

6

Universitätsklinikum Münster Klinik für Augenheilkunde

Münster, Germany

Actively Recruiting

7

Mater Misericordiae University Hospital

Dublin, Ireland

Actively Recruiting

8

Università degli Studi di Napoli Federico II

Naples, Italy

Actively Recruiting

9

Fondazione Policlinico Universitario Agostino Gemelli

Roma, Italy

Actively Recruiting

10

VISSUM

Alicante, Spain

Actively Recruiting

11

Institut OMIQ

Barcelona, Spain

Actively Recruiting

12

Hospital Universitario La Luz - Quirónsalud

Madrid, Spain

Actively Recruiting

13

Royal Victoria Hospital Belfast Health & Social Care Trust

Belfast, United Kingdom

Actively Recruiting

Loading map...

Research Team

A

Anne Roller, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here